ESMO WCGIC 2022 | How can we use ctDNA to improve adjuvant treatment for colon cancer?

Julien Taieb, MD, PhD, European Hospital Georges Pompidou, Paris, France, discusses the importance of identifying which patients with colon cancer will benefit from receiving adjuvant treatment. Circulating tumor DNA (ctDNA) can be used to identify patients with minimal residual disease (MRD) and recent research has suggested that this can be used to identify which patients need to undergo adjuvant treatment. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.